Janux Therapeutics Ownership | Who Owns Janux Therapeutics?


OverviewForecastRevenueFinancialsChart

Janux Therapeutics Ownership Summary


Janux Therapeutics is owned by 23.57% institutional investors, 6.73% insiders, and 69.71% retail investors. Ra capital management is the largest institutional shareholder, holding 18.06% of JANX shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 3.67% of its assets in Janux Therapeutics shares.

JANX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockJanux Therapeutics23.57%6.73%69.71%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management11.19M18.06%$155.54M
Blackrock funding, inc. /de5.43M8.77%$75.52M
Janus henderson group4.20M6.77%$58.28M
Prosight management, lp3.55M5.73%$49.34M
Blackrock2.34M4.78%$98.19M
Paradigm biocapital advisors lp2.92M4.72%$71.37M
Vanguard group2.91M4.69%$40.11M
Fmr2.54M4.09%$35.25M
State street2.46M3.98%$34.25M
Tcg crossover management1.79M2.89%$24.88M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Avalon ventures management53.30K9.17%$1.30M
Prosight management, lp3.55M8.09%$49.34M
Bioimpact capital614.28K2.46%$15.01M
Paradigm biocapital advisors lp2.92M2.03%$71.37M
Rangeley capital122.50K1.65%$1.70M
Ra capital management11.19M1.65%$155.54M
Lion point capital, lp19.00K1.58%$264.10K
Bml capital management154.96K1.38%$2.15M
Adar1 capital management351.03K0.81%$8.58M
Tcg crossover management1.79M0.71%$24.88M

Top Buyers

HolderShares% AssetsChange
Blackrock funding, inc. /de5.43M0.00%1.35M
Prosight management, lp3.55M8.09%1.16M
Deep track capital, lp1.19M0.27%1.10M
Holocene advisors, lp1.02M0.17%1.02M
Nantahala capital management809.91K0.41%809.91K

Top Sellers

HolderShares% AssetsChange
Ecor1 capital---1.47M
State street2.46M0.00%-1.39M
Janus henderson group4.20M0.03%-1.15M
Rtw investments, lp---1.00M
Fmr2.54M0.00%-976.66K

New Positions

HolderShares% AssetsChangeValue
Holocene advisors, lp1.02M0.17%1.02M$54.35M
Nantahala capital management809.91K0.41%809.91K$11.26M
Vanguard fiduciary trust313.65K0.00%313.65K$4.36M
Bml capital management154.96K1.38%154.96K$2.15M
Connor, clark & lunn investment management119.38K0.00%119.38K$1.66M

Sold Out

HolderChange
Corecap advisors-9.00
Srs capital advisors-14.00
Stephens consulting-15.00
Capital performance advisors llp-17.00
Abich financial wealth management-20.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026117-37.77%14,603,619-76.52%230.23%73-35.96%23-43.90%
Dec 31, 2025139-23.20%36,407,138-44.13%580.53%832.47%29-53.23%
Sep 30, 2025172-1.71%64,553,5911.68%1040.99%79-14.13%5915.69%
Jun 30, 2025180-6.25%65,438,049-1.58%1050.91%93-21.19%5323.26%
Mar 31, 20257-96.93%3,447,727-94.63%50.04%5-96.82%1-97.73%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S2.20M3.67%2.89K
Fidelity Growth Compy Commingled Pl O1.65M3.16%20.65K
State Street® SPDR® S&P® Biotech ETF1.59M2.60%-15.70K
Fidelity Growth Company Fund1.56M2.60%-9.34K
Vanguard Total Stock Mkt Idx Inv1.23M2.01%-
Vanguard US Total Market Shares ETF1.00M1.69%193.50K
iShares Russell 2000 ETF1.01M1.66%8.51K
FIAM Small Cap Core CIT Cl B912.40K1.50%-
FIAM Small Cap Core Composite734.90K1.21%734.90K
Janus Henderson Global Life Sciences719.78K1.18%754.00

Recent Insider Transactions


DateNameRoleActivityValue
May 11, 2026Dobek Maria Vice President, AccountingSell$28.88K
Jan 02, 2026Meyer Andrew Hollman Chief Business OfficerSell$25.80K
Jan 02, 2026DiRaimondo Thomas Chief Scientific OfficerSell$34.39K
Jan 02, 2026Campbell David Alan President and CEOSell$110.83K
Jan 02, 2026Winter Charles M. Chief Technical OfficerSell$32.97K

Insider Transactions Trends


DateBuySell
2026 Q2-1
2026 Q1-6
2025 Q4-4
2025 Q2-3
2025 Q1411

JANX Ownership FAQ


Who Owns Janux Therapeutics?

Janux Therapeutics shareholders are primarily institutional investors at 23.57%, followed by 6.73% insiders and 69.70% retail investors. The average institutional ownership in Janux Therapeutics's industry, Biotech Stocks , is 35.75%, which Janux Therapeutics falls below.

Who owns the most shares of Janux Therapeutics?

Janux Therapeutics’s largest shareholders are Ra capital management (11.19M shares, 18.06%), Blackrock funding, inc. /de (5.43M shares, 8.77%), and Janus henderson group (4.2M shares, 6.77%). Together, they hold 33.60% of Janux Therapeutics’s total shares outstanding.

Does Blackrock own Janux Therapeutics?

Yes, BlackRock owns 4.78% of Janux Therapeutics, totaling 2.34M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 98.19M$. In the last quarter, BlackRock increased its holdings by 650.02K shares, a 38.37% change.

Who is Janux Therapeutics’s biggest shareholder by percentage of total assets invested?

Avalon ventures management is Janux Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.17% of its assets in 53.3K Janux Therapeutics shares, valued at 1.3M$.

Who is the top mutual fund holder of Janux Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Janux Therapeutics shares, with 3.67% of its total shares outstanding invested in 2.2M Janux Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools